Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status: | Recruiting |
---|---|
Conditions: | Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/31/2019 |
Start Date: | October 27, 2014 |
End Date: | May 2024 |
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies how well dose-escalated photon intensity-modulated
radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose
radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma.
Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells
and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation
directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is
not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more
effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose
radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma.
Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells
and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation
directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is
not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more
effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
PRIMARY OBJECTIVES:
I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using
a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and
adjuvant temozolomide improves overall survival, as compared to standard-dose photon
irradiation with concomitant and adjuvant temozolomide.
SECONDARY OBJECTIVES:
I. To indirectly compare dose-escalated and -intensified photon IMRT to dose-escalated and
-intensified proton beam therapy in terms of overall survival.
II. To indirectly compare and record toxicities of dose-escalated and -intensified photon
IMRT versus dose-escalated and -intensified proton beam therapy and directly compare the
toxicities of these approaches versus standard-dose photon irradiation on the backbone of
concomitant and adjuvant temozolomide.
III. To indirectly determine if dose-escalated and -intensified proton beam therapy with
concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as
compared to dose-escalated and -intensified photon IMRT, and to directly compare symptom
burden with these approaches versus standard-dose photon irradiation on the backbone of
concomitant and adjuvant temozolomide.
IV. To indirectly determine if dose-escalated and -intensified proton beam therapy with
concomitant and adjuvant temozolomide improves neurocognitive function, as compared to
dose-escalated and -intensified photon IMRT, and to directly compare neurocognitive function
with these approaches versus standard-dose photon irradiation on the backbone of concomitant
and adjuvant temozolomide.
TERTIARY OBJECTIVES:
I. Tissue banking for future translational science projects that will be determined based on
the state of the science at the time the primary endpoint is reported and will be submitted
to National Cancer Institute (NCI) for review and approval.
II. To prospectively compare cluster of differentiation (CD)4 lymphopenia between
dose-escalated and intensified proton beam therapy, dose-escalated and -intensified photon
IMRT, and standard-dose photon irradiation.
III. To explore the most appropriate and clinically relevant technological parameters to
ensure quality and effectiveness throughout radiation therapy processes, including imaging,
simulation, patient immobilization, target and critical structure definition, treatment
planning, image guidance and delivery.
- To establish feasibility and clinical relevancy of quality assurance guidelines.
- To evaluate efficacy of quality assurance tools.
OUTLINE: Patients are assigned to 1 of 2 groups depending on enrolling institution. Within
each group, patients will be randomized 1:2 in favor of the experimental arms.
GROUP I (PHOTON IMRT CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A1: Patients undergo standard-dose photon irradiation using 3-dimensional conformal
radiation therapy (3D-CRT) or IMRT once daily (QD), 5 days a week for 23 fractions plus a
boost of 7 additional fractions.
ARM B: Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a
total of 30 fractions.
GROUP II (PROTON CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A2: Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
ARM C: Patients undergo dose-escalated and -intensified proton beam radiation therapy QD, 5
days a week for a total of 30 fractions.
In all treatment arms, patients receive temozolomide orally (PO) QD on days 1-49 of radiation
therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment
repeats every 28 days for up to 12 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for 1 year, and then every 6 months thereafter.
I. To determine if dose-escalated and -intensified photon IMRT or proton beam therapy (using
a dose-per-fraction escalation with simultaneous integrated boost) with concomitant and
adjuvant temozolomide improves overall survival, as compared to standard-dose photon
irradiation with concomitant and adjuvant temozolomide.
SECONDARY OBJECTIVES:
I. To indirectly compare dose-escalated and -intensified photon IMRT to dose-escalated and
-intensified proton beam therapy in terms of overall survival.
II. To indirectly compare and record toxicities of dose-escalated and -intensified photon
IMRT versus dose-escalated and -intensified proton beam therapy and directly compare the
toxicities of these approaches versus standard-dose photon irradiation on the backbone of
concomitant and adjuvant temozolomide.
III. To indirectly determine if dose-escalated and -intensified proton beam therapy with
concomitant and adjuvant temozolomide improves perceived cognitive symptom severity, as
compared to dose-escalated and -intensified photon IMRT, and to directly compare symptom
burden with these approaches versus standard-dose photon irradiation on the backbone of
concomitant and adjuvant temozolomide.
IV. To indirectly determine if dose-escalated and -intensified proton beam therapy with
concomitant and adjuvant temozolomide improves neurocognitive function, as compared to
dose-escalated and -intensified photon IMRT, and to directly compare neurocognitive function
with these approaches versus standard-dose photon irradiation on the backbone of concomitant
and adjuvant temozolomide.
TERTIARY OBJECTIVES:
I. Tissue banking for future translational science projects that will be determined based on
the state of the science at the time the primary endpoint is reported and will be submitted
to National Cancer Institute (NCI) for review and approval.
II. To prospectively compare cluster of differentiation (CD)4 lymphopenia between
dose-escalated and intensified proton beam therapy, dose-escalated and -intensified photon
IMRT, and standard-dose photon irradiation.
III. To explore the most appropriate and clinically relevant technological parameters to
ensure quality and effectiveness throughout radiation therapy processes, including imaging,
simulation, patient immobilization, target and critical structure definition, treatment
planning, image guidance and delivery.
- To establish feasibility and clinical relevancy of quality assurance guidelines.
- To evaluate efficacy of quality assurance tools.
OUTLINE: Patients are assigned to 1 of 2 groups depending on enrolling institution. Within
each group, patients will be randomized 1:2 in favor of the experimental arms.
GROUP I (PHOTON IMRT CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A1: Patients undergo standard-dose photon irradiation using 3-dimensional conformal
radiation therapy (3D-CRT) or IMRT once daily (QD), 5 days a week for 23 fractions plus a
boost of 7 additional fractions.
ARM B: Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a
total of 30 fractions.
GROUP II (PROTON CENTERS): Patients are randomized to 1 of 2 treatment arms.
ARM A2: Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.
ARM C: Patients undergo dose-escalated and -intensified proton beam radiation therapy QD, 5
days a week for a total of 30 fractions.
In all treatment arms, patients receive temozolomide orally (PO) QD on days 1-49 of radiation
therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment
repeats every 28 days for up to 12 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 4 months for 1 year, and then every 6 months thereafter.
Inclusion Criteria:
- PRIOR TO STEP 1 REGISTRATION
- A diagnostic contrast-enhanced magnetic resonance imaging (MRI) (no other scan type
allowed) of the brain must be performed postoperatively within 72 hours of resection;
the enhancing tumor must have a maximal diameter of 5 cm; the tumor diameter will be
the greatest diameter as measured on the contrast-enhanced postoperative MRI and will
include residual disease and/or the postoperative surgical cavity as appropriate; for
cases where residual disease or postoperative surgical cavity is NOT identifiable
(e.g., polar glioblastomas [GBMs] where a polar lobectomy is performed), the patient
will be excluded from the trial
- The GBM tumor must be located in the supratentorial compartment only (any component
involving the brain stem or cerebellum is not allowed)
- Patients must provide study-specific informed consent prior to step 1 registration
- PRIOR TO STEP 2 REGISTRATION
- Histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade
IV) confirmed by central review prior to step 2 registration
- Tumor tissue that is determined by central pathology review prior to step 2
registration to be of sufficient quantity for analysis of
O6-methylguanin-DNA-methyltransferase (MGMT) status
- Patients must have at least 1 block of tumor tissue; submission of 2 blocks is
strongly encouraged to maximize the chances of eligibility; at least 1 cubic
centimeter of tissue composed primarily of tumor must be present
- Diagnosis must be made by surgical excision, either partial or complete;
stereotactic biopsy or cavitron ultrasonic suction aspirator (CUSA) technique are
not allowed
- History/physical examination within 28 days prior to step 2 registration
- The patient must have recovered from effects of surgery, postoperative infection, and
other complications within 28 days prior to step 2 registration
- Documentation of steroid doses within 28 days prior to step 2 registration
- Karnofsky performance status >= 70 within 28 days prior to step 2 registration
- Age >= 18
- Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
- Platelets >= 100,000 cells/mm^3
- Hemoglobin >= 10.0 g/dl (note: the use of transfusion or other intervention to achieve
hemoglobin (Hgb) >= 10.0 g/dl is acceptable)
- Bilirubin =< 1.5 upper limit of normal (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
- Negative serum pregnancy test obtained for females of child-bearing potential within
28 days prior to step 2 registration
Exclusion Criteria:
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free
for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity,
or cervix are all permissible)
- Recurrent or multifocal malignant gliomas
- Any site of distant disease (for example, drop metastases from the GBM tumor site)
- Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note
that prior chemotherapy for a different cancer is allowable (except temozolomide)
- Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are
not permitted
- Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in
overlap of radiation fields
- Severe, active co-morbidity, defined as follows:
- Unstable angina at step 2 registration
- Transmural myocardial infarction within the last 6 months prior to step 2
registration
- Evidence of recent myocardial infarction or ischemia by the findings of S-T
elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed
within 28 days prior to step 2 registration
- New York Heart Association grade II or greater congestive heart failure requiring
hospitalization within 12 months prior to step 2 registration
- Serious and inadequately controlled arrhythmia at step 2 registration
- Serious or non-healing wound, ulcer or bone fracture or history of abdominal
fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy
or significant traumatic injury within 28 days prior to step 2 registration, with
the exception of the craniotomy for surgical resection
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time
of step 2 registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
note, however, that laboratory tests for coagulation parameters are not required
for entry into this protocol
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization or precluding study therapy at the time of step 2
registration
- Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
Control and Prevention (CDC) definition; note, however, that human
immunodeficiency virus (HIV) testing is not required for entry into this protocol
- Any other severe immunocompromised condition
- Active connective tissue disorders, such as lupus or scleroderma, that in the
opinion of the treating physician may put the patient at high risk for radiation
toxicity
- End-stage renal disease (ie, on dialysis or dialysis has been recommended)
- Any other major medical illnesses or psychiatric treatments that in the
investigator's opinion will prevent administration or completion of protocol
therapy
- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception
- Patents treated on any other therapeutic clinical protocols within 30 days prior to
step 2 registration
- Inability to undergo MRI (e.g., due to safety reasons, such as presence of a
pacemaker, or severe claustrophobia)
- Postoperative tumor plus surgical bed size exceeds 5 cm in maximum diameter.
We found this trial at
226
sites
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: John E. Mignano
Phone: 617-636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Todd A. Swanson
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
655 West 8th Street
Jacksonville, Florida 32209
Jacksonville, Florida 32209
Principal Investigator: Ronny L. Rotondo
Phone: 412-339-5294
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Sanjay Maraboyina
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Stephen L. Shiao
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Timothy J. Harris
Phone: 412-339-5294
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Richard L. Crownover
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Mitchel L. Fromm
Phone: 866-223-8100
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Michelle M. Kim
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Darryl R. Barton
Phone: 877-405-6866
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Hui-Kuo G. Shu
Phone: 404-778-1868
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
Austin, Texas 78702
Principal Investigator: Brian D. Vaillant
Phone: 412-339-5294
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Vivek S. Kavadi
Phone: 512-421-4163
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Vivek S. Kavadi
Phone: 512-427-9400
Click here to add this to my saved trials
Austin, Texas 78745
Principal Investigator: Vivek S. Kavadi
Phone: 512-447-2202
Click here to add this to my saved trials
Austin, Texas 78758
Principal Investigator: Brian D. Vaillant
Phone: 512-324-3399
Click here to add this to my saved trials
1500 Red River Street
Austin, Texas 78701
Austin, Texas 78701
Principal Investigator: Brian D. Vaillant
Phone: 512-324-7991
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Ruben C. Fragoso
Phone: 661-323-4673
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Mark V. Mishra
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
Baltimore, Maryland 21201
Principal Investigator: Mark V. Mishra
Phone: 410-369-5226
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Mariza Daras
Phone: 212-639-5007
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Click here to add this to my saved trials
Bel Air, Maryland 21014
Principal Investigator: Jack J. Hong
Phone: 443-643-3010
Click here to add this to my saved trials
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Carl J. Nelson
Phone: 802-225-5400
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nimisha Deb
Phone: 412-339-5294
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: John B. Fiveash
Phone: 205-934-0309
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Helen A. Shih
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Madhur K. Garg
Phone: 718-904-2730
Click here to add this to my saved trials
263 7th Avenue
Brooklyn, New York 11215
Brooklyn, New York 11215
Principal Investigator: Hani L. Ashamalla
Phone: 718-780-3677
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Carl J. Nelson
Phone: 802-656-4101
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Christopher U. Jones
Phone: 510-537-1234
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Samuel L. Cooper
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Timothy J. Kruser
Phone: 312-695-1301
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 864-6000
Principal Investigator: Thomas E. Lad
Phone: 312-864-5204
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Steven J. Chmura
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Aidnag Z. Diaz
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Samuel T. Chao
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Samuel T. Chao
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Colorado Springs, Colorado 80909
Principal Investigator: Anthony D. Elias
Phone: 719-365-2406
Click here to add this to my saved trials
Columbia, Maryland 21044
Principal Investigator: Mark V. Mishra
Phone: 443-546-1300
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Arnab Chakravarti
Phone: 800-293-5066
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: John P. Kuebler
Phone: 614-488-2745
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
Click here to add this to my saved trials
Commack, New York 11725
Principal Investigator: Mariza Daras
Phone: 631-623-4000
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Robert D. Timmerman
Phone: 214-648-7097
Click here to add this to my saved trials
Danvers, Massachusetts 01923
Principal Investigator: Helen A. Shih
Phone: 978-882-6032
Click here to add this to my saved trials
Dearborn, Michigan 48124
Principal Investigator: Prakash Chinnaiyan
Phone: 313-593-8090
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
1 Kish Hospital Drive
DeKalb, Illinois 60115
DeKalb, Illinois 60115
Principal Investigator: Vinai Gondi
Phone: 815-756-5255
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-3309
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Eleanor M. Walker
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
Click here to add this to my saved trials
Duluth, Minnesota 55805
Principal Investigator: Steven R. Bonin
Phone: 412-339-5294
Click here to add this to my saved trials
Dunmore, Pennsylvania 18512
Principal Investigator: Wenyin Shi
Phone: 888-808-6762
Click here to add this to my saved trials
Elyria, Ohio 44035
Principal Investigator: Mitchell Machtay
Phone: 800-641-2422
Click here to add this to my saved trials
Ephrata, Pennsylvania 17522
Principal Investigator: Amit B. Shah
Phone: 717-721-4840
Click here to add this to my saved trials
Eugene, Oregon 97401
Principal Investigator: Vivek S. Kavadi
Phone: 541-681-4930
Click here to add this to my saved trials
820 4th St N
Fargo, North Dakota 58102
Fargo, North Dakota 58102
(701) 234-6161
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Roger Maris Cancer Center Sanford Health is an integrated health system headquartered in the Dakotas...
Click here to add this to my saved trials
Flint, Michigan 48532
Principal Investigator: Michael M. Dominello
Phone: 313-576-9363
Click here to add this to my saved trials
Flower Mound, Texas 75028
Principal Investigator: Vivek S. Kavadi
Phone: 972-537-4100
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Anthony D. Elias
Phone: 970-297-6150
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
Fort Wayne, Indiana 46804
Principal Investigator: Brian K. Chang
Phone: 877-437-2408
Click here to add this to my saved trials
2200 Randallia Drive
Fort Wayne, Indiana 46805
Fort Wayne, Indiana 46805
Principal Investigator: Brian K. Chang
Phone: 260-373-8888
Click here to add this to my saved trials
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Gainesville, Florida 32610
Click here to add this to my saved trials
Geneva, Illinois 60134
Principal Investigator: Vinai Gondi
Phone: 630-315-1918
Click here to add this to my saved trials
40 V-Twin Drive
Gettysburg, Pennsylvania 17325
Gettysburg, Pennsylvania 17325
(717) 339-2640
Principal Investigator: Amit B. Shah
Phone: 877-441-7957
Adams Cancer Center Every day across central Pennsylvania, the people of WellSpan Health work together...
Click here to add this to my saved trials
Glen Burnie, Maryland 21061
Principal Investigator: Mark V. Mishra
Phone: 410-553-8100
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
Click here to add this to my saved trials
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
Greenwood, South Carolina 29646
Principal Investigator: Samuel L. Cooper
Phone: 843-792-9321
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
24800 SE Stark St
Gresham, Oregon 97030
Gresham, Oregon 97030
(503) 674-1122
Principal Investigator: Andrew Y. Kee
Phone: 503-413-2150
Legacy Mount Hood Medical Center Legacy Mount Hood Medical Center, East County's full-service community hospital,...
Click here to add this to my saved trials
4300 Londonderry Road
Harrisburg, Pennsylvania 17109
Harrisburg, Pennsylvania 17109
Principal Investigator: David C. Weksberg
Phone: 717-724-6765
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Harrison, New York 10604
Principal Investigator: Mariza Daras
Phone: 212-639-7592
Click here to add this to my saved trials
80 Seymour St
Hartford, Connecticut 6102
Hartford, Connecticut 6102
(860) 545-5000
Principal Investigator: Susan Y. Kim
Phone: 860-545-5363
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: Vivek S. Kavadi
Phone: 281-277-5200
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Andrew J. Bishop
Phone: 877-312-3961
Click here to add this to my saved trials
Independence, Ohio 44131
Principal Investigator: Samuel T. Chao
Phone: 866-223-8100
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Gordon A. Watson
Phone: 317-278-5632
Click here to add this to my saved trials
Indianapolis, Indiana 46227
Principal Investigator: Daniel W. Weed
Phone: 317-621-7104
Click here to add this to my saved trials